This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence, frequency, and severity of adverse events (AEs)
Timeframe: Day 0 to day 337
Changes from baseline in laboratory parameters including general biochemistry, lipid profile, coagulation, hematology, and urinalysis
Timeframe: Day 0 to day 337
Changes from baseline in physical examination
Timeframe: Day 0 to day 337
Changes from baseline in vital signs
Timeframe: Day 0 to day 337
Changes from baseline in 12-lead safety ECGs
Timeframe: Day 0 to day 337
Incidence and severity of injection site reactions
Timeframe: Day 0 to day 337